Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor T-lymphocytes
- Development stage
- Phase 2
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor T-lymphocytes, often administered as a Donor Lymphocyte Infusion (DLI), are a form of adoptive cellular immunotherapy used primarily in the setting of allogeneic hematopoietic stem cell transplantation (HSCT). In the specific clinical protocol developed by the M.D. Anderson Cancer Center, these donor-derived CD3+ T-cells are infused into the patient approximately 8-9 weeks following a reduced-intensity transplant. The therapeutic rationale is to induce a "graft-versus-tumor" (GVT) effect, wherein the donor's immune cells recognize and eliminate residual malignant cells in the recipient that may have survived the initial transplant conditioning. This approach is being investigated to reduce the risk of disease relapse in patients with various hematologic malignancies, including leukemia, myelodysplastic syndrome (MDS), lymphoma, Hodgkin lymphoma, and multiple myeloma.
- Other names
- Donor Lymphocyte InfusionDLIDonor T-cellsCD3+ cellsPlanned Donor Lymphocyte Infusion
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on donor T-lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor T-lymphocytes.